Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Apolipoprotein M in patients with chronic kidney disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Response to Letter to the Editor: "Familial Hypercholesterolemia and Risk of Peripheral Arterial Disease and Chronic Kidney Disease"

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  • The EAS Familial Hypercholeserolaemia Studies Collaboration (FHSC)
View graph of relations

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

Original languageEnglish
JournalAtherosclerosis
Volume277
Pages (from-to)234-255
Number of pages22
ISSN0021-9150
DOIs
Publication statusPublished - 10 Oct 2018

    Research areas

  • Familial hypercholesterolaemia, FHSC, Primary dyslipidaemia

ID: 55676612